IN-VITRO EFFICACY EVALUATION OF ANTIMICROBIAL COMBINATION ON PNEUMOCOCCAL-INFECTED- COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN

Nguyễn Thị Nam Phong1, Phạm Viết Tín1, Võ Đình Sơn1, Trần Thị Thúy Nga1, Đỗ Thị Hồng Tươi2,
1 Danang University of Medical Technology and Pharmacy
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Introduction: Antibiotics and combination regimens are of importance in the treatment of Community-Acquired Pneumonia (CAP). In the face of the rapid emergence of multidrug-resistant pneumococcal strains, it is necessary to re-evaluate the efficacy of combination therapies to support controlling antimicrobial resistance and selecting appropriate regimens for the treatment of CAP. Objectives: To investigate the synergistic effect of some commonly used combination therapy for the treatment of CAP on multidrug-resistant pneumococcal isolates. Methods: The experimental study was conducted to evaluate the synergistic effects of several dual antimicrobial therapies on multidrug-resistant pneumococcal isolates using E-test methods. Results: The presence of azithromycin, gentamicin reduced the MIC of antibiotics used in combination with cefotaxime, ceftriaxone on the pneumococcal strains. Gentamicin-plus-cefotaxime and gentamicin-plus-ceftriaxone combinations showed the additive antimicrobial effects on the pneumococcal strain Pca; however, there were no clear synergistic activities. Macrolide and beta-lactam combinations have not shown in vitro synergistic bactericidal effects. Conclusions: In the case of CAP induced by multidrug-resistant Streptococcus pneumoniae, combining macrolides and β-lactams does not produce in vitro synergistic effects. The clinicians should carefully consider the selection of appropriate antibiotic combinations to enhance the treatment efficacy.

Article Details

References

1. Nguyễn TX, Lương NK, Trần Q, Hoàng TKH. Hướng dẫn sử dụng kháng sinh. Hà Nội: Nhà xuất bản Y học; 2015.
2. Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Annals of intensive care. 2011;1:48.
3. Larsson M, Nguyen HQ, Olson L, Tran TK, Nguyen TV, Nguyen CTK. Multi-drug resistance in Streptococcus pneumoniae among children in rural Vietnam more than doubled from 1999 to 2014. Acta Paediatrica. 2021;110(6):1916-23.
4. M07-A9 C. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Edition N, editor: Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
5. Liofilchem. MIC Test Strip Technical Sheet Synergy Testing 2016. Available from: http://www.liofilchem.net/login.area.mic/technical_sheets/MTS31.pdf.
6. M100-S21 C. Performance Standards for Antimicrobial Susceptibility Testing. Edition AS-s, editor. Wayne: Clinical and Laboratory Standards Institude; 2011.
7. Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrobial agents and chemotherapy. 2003;47(3):1151-3.
8. Washington JA, 2nd. Discrepancies between in vitro activity of and in vivo response to antimicrobial agents. Diagnostic microbiology and infectious disease. 1983;1(1):25-31.
9. Ruppen C, Decosterd L, Sendi P. Is gentamicin necessary in the antimicrobial treatment for group B streptococcal infections in the elderly? An in vitro study with human blood products. Infectious diseases (London, England). 2017;49(3):185-92.
10. Paul M, Lador A, Grozinsky‐Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Systematic Reviews. 2014(1).